LACTOLOGY FOUNDATION

Toxicological and Lactological Profile of ATC Class A09AB (Acid Preparations)

ATC Class and General Pharmacology

The Anatomical Therapeutic Chemical (ATC) classification system, developed and maintained by the World Health Organization (WHO), categorizes acidifying digestive preparations under code A09AB. This subgroup represents a specialized chemical division within the broader hierarchical structure of the classification system:   

·        Main Anatomical Group A: Alimentary Tract and Metabolism   

·        Therapeutic Subgroup A09: Digestives, including Enzymes   

·        Pharmacological Subgroup A09A: Digestives, including Enzymes   

·        Chemical Subgroup A09AB: Acid Preparations   

The A09AB subgroup encompasses both organic and inorganic acid preparations designed to restore physiological intragastric acidity in individuals with impaired gastric secretion. Active substances categorized within this class include glutamic acid hydrochloride (A09AB01), betaine hydrochloride (A09AB02), hydrochloric acid (A09AB03), citric acid (A09AB04), and fixed combination products combining acidifying agents with auxiliary digestive components. In accordance with the introductory, overarching scope of this monograph, individual active pharmaceutical ingredients are highlighted in general operational terms, reserving agent-specific pharmacokinetic and clinical profiling for dedicated subsequent monographs.   

The primary pharmacodynamic objective of A09AB acid preparations is the treatment of gastric hypochlorhydria or achlorhydria, pathological or age-related states characterized by insufficient endogenous secretion of hydrochloric acid by gastric parietal cells. Under healthy physiological conditions, the gastric mucosa maintains an intragastric pH between 1.5 and 2.5. Exogenous acid preparations act by releasing free hydrogen ions (H+) directly into the lumen of the stomach, thereby lowering intragastric pH and re-establishing an acidic environment. Luminal acidification initiates several critical digestive processes. A reduction in gastric pH below 3.0 triggers the autocatalytic cleavage of zymogen pepsinogen into active pepsin, an essential endopeptidase required for protein cleavage. Concurrently, adequate acidity facilitates the ionization, solubilization, and subsequent intestinal absorption of essential dietary minerals, including divalent iron (Fe2+), calcium (Ca2+), and magnesium (Mg2+). Acidification is also necessary to liberate dietary cobalamin (vitamin B12​) from binding proteins, enabling its complexation with intrinsic factor. Beyond digestive facilitating roles, maintaining a strongly acidic gastric milieu serves as a primary innate antimicrobial barrier against ingested pathogens and prevents bacterial overgrowth in the proximal small intestine.   

Pharmacokinetically, A09AB preparations act locally within the gastric lumen, followed by rapid physiological neutralization upon transit into the lower gastrointestinal tract. Following oral ingestion and gastric dispersion, the acidic chyme empties into the duodenum, where the lowered luminal pH stimulates S-cells in the duodenal mucosa to release secretin. Secretin acts on the exocrine pancreas to induce the secretion of sodium bicarbonate (NaHCO3​), which neutralizes exogenous protons (H++HCO3−​→H2​O+CO2​). The liberated organic and inorganic counter-ions—such as L-glutamate, trimethylglycine (betaine), citrate, and chloride—are subsequently processed via routine endogenous metabolic and transport pathways. Glutamate and betaine are transported across enterocytes via specific amino acid and organic cation transporters to enter intermediary metabolic cycles, whereas citric acid is integrated into the mitochondrial tricarboxylic acid (TCA) cycle.   

Toxicological Profile

The toxicological assessment of ATC class A09AB agents requires distinguishing between the local corrosive hazards associated with concentrated active chemicals and the systemic responses that occur during acute overdose or prolonged high-dose administration. In concentrated raw chemical forms, inorganic acidifiers like hydrochloric acid and solid hydrochloride salts such as glutamic acid hydrochloride display strong irritant and corrosive properties, carrying regulatory hazard classifications such as Skin Corrosion Category 1A (H314: Causes severe skin burns and eye damage). Although commercial pharmaceutical formulations dilute or encapsulate these compounds to protect upper oral and esophageal tissues, local gastrointestinal mucosal irritation remains the primary adverse toxicological feature of oral therapeutic use.   

Administration of therapeutic doses of A09AB acid preparations can cause localized upper gastrointestinal adverse reactions, including epigastric pyrosis, stomach discomfort, retrosternal burning, and nausea. In patients with impaired mucosal protection—such as individuals with active peptic ulcer disease, erosive gastritis, or severe gastroesophageal reflux disease (GERD)—exogenous acidifying agents exacerbate mucosal erosion, delay tissue healing, and increase the risk of acute gastrointestinal bleeding.   

Systemic toxicity resulting from standard oral doses of A09AB preparations is rare in individuals with normal hepatic and renal function, as duodenal secretin-mediated bicarbonate secretion neutralizes luminal acid loads. However, massive acute overdose or chronic excessive intake can exceed systemic homeostatic capacity, particularly the carbonic acid-bicarbonate (H2​CO3​/HCO3−​) buffering system. Ingestion of large quantities of chloride-containing acidifiers (such as hydrochloric acid, betaine hydrochloride, or glutamic acid hydrochloride) delivers an excessive load of exogenous protons and chloride ions (Cl−) into the systemic circulation, which can precipitate hyperchloremic metabolic acidosis characterized by reduced plasma bicarbonate concentrations and a normal anion gap.   

Specific counter-ions released by A09AB compounds present distinct toxicological considerations. Glutamic acid hydrochloride liberates L-glutamate, a major excitatory neurotransmitter in the central nervous system. Although first-pass intestinal and hepatic metabolism rapidly converts ingested glutamate into alpha-ketoglutarate under physiological conditions, extreme overdoses could theoretically elevate systemic plasma glutamate levels and challenge blood-brain barrier transport mechanisms. Similarly, citric acid and citrate salts act as chelators of multivalent cations, particularly ionized calcium (Ca2+). While ingested citric acid is rapidly oxidized via cellular metabolism, massive systemic absorption of unoxidized citrate can induce transient hypocalcemia, manifesting clinically as neuromuscular hyperexcitability or cardiac rhythm alterations.   

Lactation Pharmacology and Infant Exposure

Evaluating the excretion of A09AB acid preparations into human breast milk requires an analysis of maternal systemic pharmacokinetics and mammary gland transport mechanisms. Drug passage into milk typically depends on low maternal plasma protein binding, high lipophilicity, a low degree of ionization at physiological plasma pH (pH≈7.4), and elevated maternal systemic drug concentrations. However, A09AB acid preparations represent a unique pharmacological category because their primary active species—free hydrogen ions (H+)—exert their therapeutic effect locally within the maternal gastrointestinal lumen and are neutralized in the duodenum. Consequently, oral administration of therapeutic doses does not alter maternal systemic blood pH or systemic proton concentrations, preventing any direct passage of acidic protons into human milk and leaving breast milk pH unaffected.   

The counter-ions associated with A09AB preparations, including L-glutamate, betaine, and citrate, are endogenous, physiological constituents of human breast milk that serve crucial nutritional and developmental functions for the breastfed infant. Transport of these organic moieties into breast milk is regulated by maternal metabolic pathways and specialized transport mechanisms within the lactating mammary epithelium. Betaine naturally accumulates in human milk to maintain osmoprotection and supply methyl donors for infant growth; clinical evidence indicates that maternal dietary or supplemental betaine intake produces modest, physiological elevations in milk betaine levels that are well tolerated by infants. Maternal oral intake of glutamic acid hydrochloride does not produce significant fluctuations in milk glutamate content because maternal plasma glutamate levels are tightly controlled by hepatic metabolism, and mammary epithelial transport of free amino acids is saturable and homeostatically buffered. Similarly, citric acid content in human milk is governed by active intracellular synthesis within the Golgi apparatus of lactating cells, where it plays a key role in complexing calcium and maintaining milk osmolality, rendering milk citrate levels independent of maternal oral citric acid intake.   

Quantifying infant drug exposure through breast milk involves calculating the Relative Infant Dose (RID), defined as the daily weight-adjusted dose ingested by the infant via milk expressed as a percentage of the maternal daily weight-adjusted dose. For the free acidifying hydrogen ions of A09AB preparations, maternal systemic bioavailability to the mammary gland is zero, resulting in an RID of 0%. For the constituent organic counter-ions, the incremental excretion into breast milk above physiological baseline levels yields an estimated RID well below the established 10% threshold of clinical concern, typically registering at <1%. Furthermore, because these endogenous counter-ions undergo rapid primary degradation via infant hepatic and intestinal metabolic pathways, infant systemic bioaccumulation does not occur.

Lactological Safety Assessment and Clinical Recommendations

From a toxicological and lactological perspective, products within ATC class A09AB exhibit a highly favorable safety profile during lactation. Because these preparations act locally within the maternal gastrointestinal lumen and undergo physiological neutralization prior to systemic absorption, they present virtually no risk of inducing systemic toxicity, acid-base imbalances, or adverse metabolic changes in the breastfed infant. When a lactating mother requires digestive acidification for verified hypochlorhydria or associated dyspeptic disorders, treatment with A09AB agents is fully compatible with continued, uninterrupted breastfeeding.   

Clinical practice guidelines for prescribing A09AB preparations to nursing mothers emphasize diagnostic precision and maternal mucosal protection. Clinicians should confirm the indication for acidifying therapy rather than recommending empirical high-dose supplementation, thereby minimizing maternal gastrointestinal adverse effects. Active peptic ulceration, erosive gastritis, and unmanaged gastroesophageal reflux represent key maternal contraindications, as exogenous acid can exacerbate mucosal damage. To optimize maternal tolerance, oral acid preparations should be taken during or immediately following meals, allowing dietary proteins to buffer the initial acid load and reducing epigastric discomfort. Furthermore, standardized solid oral dosage forms, such as enteric or film-coated tablets and capsules, are preferred over unbuffered liquid solutions to protect maternal dental enamel and esophageal tissue from direct chemical irritation.   

Direct biochemical or laboratory monitoring of the breastfed infant is unnecessary during maternal therapy with A09AB preparations due to the negligible level of systemic infant exposure. Standard pediatric clinical monitoring should focus on routine observation of infant gastrointestinal tolerance, such as noting stool consistency and feeding patterns. In rare instances where an infant presents with transient stool changes or mild irritability, maternal dosing schedules or underlying dietary factors should be reviewed, although a direct toxicological link to maternal A09AB use remains highly improbable.